Bosera Medical is a hybrid fund, with stocks as the main asset allocation, and the proportion of stock investment is 60%-95% of the fund assets, which has high investment risk. In the past six months, the fund has increased by 54.7 1%, ranking as 1/2852. In recent March, the growth rate of this fund was 14.66%, ranking the top 205/2,965 of its kind. From the perspective of the medical industry, this fund can be said to be far superior to other peers, exceeding the second place by more than ten points.
Its top ten positions are large-cap stocks in the health care industry, which performed very well in the second quarter. For example, Qi Xing ophthalmology performed strongly, rising from a dozen at the beginning of the year to more than 90 now, while others such as Aier Ophthalmology, Hengrui Pharma, Mindray Medical, Changchun Hi-Tech and Fan Jian Bio all increased by more than 50%.
In terms of asset allocation, this fund has maintained 80% positions this year, and other assets are basically cash. If you are an investor with high risk tolerance, you can add your own choices and pay more attention before making a decision. However, if the risk tolerance is low, it is best to pay attention to the funds with above-average performance in the medical industry without taking additional risks.